ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ZEG - GB0009895292 - Common Stock
163.5 EUR
+1.4 (+0.86%)
ZEG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. While ZEG belongs to the best of the industry regarding profitability, there are concerns on its financial health. ZEG is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ZEG had positive earnings in the past year.
In the past year ZEG had a positive cash flow from operations.
In the past 5 years ZEG has always been profitable.
Each year in the past 5 years ZEG had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.21%, ZEG is in the better half of the industry, outperforming 65.45% of the companies in the same industry.
ZEG has a Return On Equity of 20.48%. This is in the better half of the industry: ZEG outperforms 69.09% of its industry peers.
With a decent Return On Invested Capital value of 14.42%, ZEG is doing good in the industry, outperforming 72.73% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ZEG is below the industry average of 13.65%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
The Profit Margin of ZEG (16.17%) is better than 65.45% of its industry peers.
In the last couple of years the Profit Margin of ZEG has grown nicely.
ZEG's Operating Margin of 24.34% is fine compared to the rest of the industry. ZEG outperforms 61.82% of its industry peers.
In the last couple of years the Operating Margin of ZEG has grown nicely.
ZEG has a better Gross Margin (81.90%) than 81.82% of its industry peers.
ZEG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZEG is still creating some value.
ZEG has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for ZEG has been increased compared to 5 years ago.
Compared to 1 year ago, ZEG has a worse debt to assets ratio.
2.2 Solvency
ZEG has an Altman-Z score of 6.20. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.20, ZEG belongs to the top of the industry, outperforming 83.64% of the companies in the same industry.
ZEG has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as ZEG would need 3.41 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.41, ZEG is in line with its industry, outperforming 58.18% of the companies in the same industry.
A Debt/Equity ratio of 0.61 indicates that ZEG is somewhat dependend on debt financing.
ZEG has a Debt to Equity ratio of 0.61. This is comparable to the rest of the industry: ZEG outperforms 49.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 6.2 |
ROIC/WACC1.6
WACC9.02%
2.3 Liquidity
ZEG has a Current Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.88, ZEG is doing worse than 81.82% of the companies in the same industry.
A Quick Ratio of 0.69 indicates that ZEG may have some problems paying its short term obligations.
With a Quick ratio value of 0.69, ZEG is not doing good in the industry: 78.18% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
ZEG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
ZEG shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.52%.
The Revenue has been growing by 17.27% on average over the past years. This is quite good.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
Based on estimates for the next years, ZEG will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.45% on average per year.
ZEG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.17% yearly.
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.93, the valuation of ZEG can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ZEG is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 27.00. ZEG is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 18.37, ZEG is valued on the expensive side.
ZEG's Price/Forward Earnings is on the same level as the industry average.
ZEG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.70, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.93 | ||
| Fwd PE | 18.37 |
4.2 Price Multiples
69.09% of the companies in the same industry are cheaper than ZEG, based on the Enterprise Value to EBITDA ratio.
65.45% of the companies in the same industry are cheaper than ZEG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.91 | ||
| EV/EBITDA | 29.78 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ZEG may justify a higher PE ratio.
ZEG's earnings are expected to grow with 12.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.75
PEG (5Y)1.13
EPS Next 2Y12.55%
EPS Next 3Y12.2%
5. Dividend
5.1 Amount
ZEG has a Yearly Dividend Yield of 1.77%.
ZEG's Dividend Yield is a higher than the industry average which is at 1.60.
Compared to an average S&P500 Dividend Yield of 1.94, ZEG has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.77% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
ZEG pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
ZEG's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP52.89%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
FRA:ZEG (1/8/2026, 7:00:00 PM)
163.5
+1.4 (+0.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners49.17%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap506.94B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target166.38 (1.76%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.77% |
Yearly Dividend2.54
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)3.89%
PT rev (3m)7.43%
EPS NQ rev (1m)1.34%
EPS NQ rev (3m)-0.73%
EPS NY rev (1m)-1.9%
EPS NY rev (3m)-1.57%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)0.23%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.93 | ||
| Fwd PE | 18.37 | ||
| P/S | 10.19 | ||
| P/FCF | 61.91 | ||
| P/OCF | 39.12 | ||
| P/B | 12.91 | ||
| P/tB | N/A | ||
| EV/EBITDA | 29.78 |
EPS(TTM)7.81
EY4.78%
EPS(NY)8.9
Fwd EY5.44%
FCF(TTM)2.64
FCFY1.62%
OCF(TTM)4.18
OCFY2.56%
SpS16.05
BVpS12.67
TBVpS-3.73
PEG (NY)1.75
PEG (5Y)1.13
Graham Number47.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 6.2 |
F-Score7
WACC9.02%
ROIC/WACC1.6
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status of ASTRAZENECA PLC (ZEG.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
What is the valuation of ASTRAZENECA PLC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 20.93 and the Price/Book (PB) ratio is 12.91.
Can you provide the expected EPS growth for ZEG stock?
The Earnings per Share (EPS) of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 11.95% in the next year.